Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel